Gilead swings to $10.5B loss on $11.2B acquisition IPR&D and $1.75B Trodelvy impairment; revenue up 10.2%

Filed August 6, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 7, 2025 · ~1 min read

Key Changes

• high

  Net loss of vs. $2.0B profit a year ago, driven by acquired IPR&D from Arcellx, Tubulis, and Ouro Medicines acquisitions and a Trodelvy impairment.

  MD&A: Net loss verify on EDGAR →
• high

  Acquired IPR&D expenses of $11.2B in Q2 2026 (vs. $61M a year ago) from three acquisitions: Arcellx, Tubulis, and Ouro Medicines.

  MD&A: Acquired IPR&D verify on EDGAR →
• high

  Trodelvy NSCLC IPR&D asset fully impaired for $1.75B after discontinuing Phase 3 EVOKE-03 study; removes a key oncology expansion opportunity.

  MD&A: IPR&D impairment verify on EDGAR →